Cardinal (CAH) Upgraded to Buy: Here's Why
Cardinal (CAH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Should Value Investors Buy Cardinal Health (CAH) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health, Northrop Grumman Among 7 Companies To Announce Dividend Increases In First Half Of May
This is my latest article where I provide predictions of upcoming dividend increases from companies with long-term dividend growth histories. Industrial engineering company Parker-Hannifin announced its latest payout boost, becoming one of less than a handful of companies with a 70-year dividend growth streak. Investors can expect modest increases from several companies in the first half of May, including a 10% increase from defense company Northrop Grumman.
Why Cardinal Health (CAH) is a Top Value Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Cardinal Health, Inc. (CAH) Q3 2025 Earnings Call Transcript
Cardinal Health, Inc. (NYSE:CAH ) Q3 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Matt Sims - Vice President, Investor Relations Jason Hollar - Chief Executive Officer Aaron Alt - Chief Financial Officer Conference Call Participants Lisa Gill - JPMorgan Allen Lutz - Bank of America Joanna Dynak - Evercore Eric Percher - Nephron Michael Cherny - Leerink Partners Kevin Caliendo - UBS George Hill - Deutsche Bank Eric Coldwell - Baird Erin Wright - Morgan Stanley Daniel Grosslight - Citi Charles Rhyee - TD Cowen Steve Baxter - Wells Fargo Brian Tanquilut - Jefferies Steven Valiquette - Mizuho Operator Hello, and welcome to the Third Quarter Fiscal Year 2025 Cardinal Health Incorporated Earnings Conference Call. My name is George, and I'll be the coordinator for today's event.
CAH Q3 Earnings Beat Estimates, '25 EPS View Raised, Stock Gains
Cardinal Health's third-quarter fiscal 2025 results benefit from solid Medical and Other segment revenue growth. However, OptumRx contract expiry hurts Pharmaceutical segment sales.
Cardinal (CAH) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Cardinal (CAH) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Cardinal Health (CAH) Beats Q3 Earnings Estimates
Cardinal Health (CAH) came out with quarterly earnings of $2.35 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.08 per share a year ago.
Can Sustained Product Demand Drive CAH Stock Before Q3 Earnings?
The continued solid uptake of Cardinal Health's products is expected to have driven fiscal third-quarter revenues despite an uncertain macroeconomic environment.
Cardinal (CAH) Q3 Earnings Preview: What You Should Know Beyond the Headline Estimates
Evaluate the expected performance of Cardinal (CAH) for the quarter ended March 2025, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Cardinal Health (CAH) Reports Next Week: Wall Street Expects Earnings Growth
Cardinal (CAH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
